Nektar Therapeutics Stock Today

NKTR Stock  USD 0.85  0.01  1.16%   

Performance

13 of 100

 
Low
 
High
Good

Odds Of Distress

Over 67

 
100  
 
Zero
Quite High
Nektar Therapeutics is selling at 0.85 as of the 18th of March 2024; that is -1.16 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.83. Nektar Therapeutics has more than 67 % chance of experiencing financial distress in the next few years of operation. However, it had a very good returns during the last 90 days. Equity ratings for Nektar Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of February 2024 and ending today, the 18th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of May 1994
Category
Healthcare
Classification
Health Care
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. The company has 183.62 M outstanding shares of which 2.01 M shares are now shorted by private and institutional investors with about 1.41 trading days to cover. More on Nektar Therapeutics

Moving together with Nektar Stock

  0.68A Agilent Technologies Financial Report 28th of May 2024 PairCorr

Moving against Nektar Stock

  0.93AKAN Akanda Corp Report 6th of May 2024 PairCorr
  0.78MYMD MyMD Pharmaceuticals Report 29th of March 2024 PairCorr
  0.77VALN Valneva SE ADR Earnings Call This WeekPairCorr
  0.69IMMX Immix Biopharma Report 25th of March 2024 PairCorr
  0.57ABCL Abcellera BiologicsInc Financial Report 2nd of May 2024 PairCorr
  0.54FLGC Flora Growth Corp Report 29th of March 2024 PairCorr
  0.44PTN Palatin Technologies Financial Report 21st of May 2024 PairCorr

Nektar Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Nektar Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Nektar Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and DirectorHoward Robin
Thematic IdeaTrump Equities (View all Themes)
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Trump Equities, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Nektar Therapeutics report their recommendations after researching Nektar Therapeutics' financial statements, talking to executives and customers, or listening in on Nektar Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Nektar Therapeutics. The Nektar consensus assessment is calculated by taking the average forecast from all of the analysts covering Nektar Therapeutics.
Financial Strength
Based on the key indicators related to Nektar Therapeutics' liquidity, profitability, solvency, and operating efficiency, Nektar Therapeutics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April. Financial strength of Nektar Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.180.2264
Significantly Down
Pretty Stable
Gross Profit Margin0.90.5934
Way Up
Pretty Stable
Total Current Liabilities88.1 M51.3 M
Way Up
Very volatile
Non Current Liabilities Total301.7 M215.8 M
Significantly Up
Pretty Stable
Total Assets707.3 M398 M
Way Up
Slightly volatile
Total Current Assets476.4 M330.7 M
Way Up
Slightly volatile
Nektar Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Nektar Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nektar Therapeutics' financial leverage. It provides some insight into what part of Nektar Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Nektar Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Nektar Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Nektar Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 230.4 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Nektar Therapeutics has a current ratio of 7.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Nektar Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nektar Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nektar Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nektar to invest in growth at high rates of return. When we think about Nektar Therapeutics' use of debt, we should always consider it together with cash and equity.

Capital Expenditures

821,750
Nektar Therapeutics (NKTR) is traded on NASDAQ Exchange in USA. It is located in 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 and employs 137 people. Nektar Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 157.95 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Nektar Therapeutics's market, we take the total number of its shares issued and multiply it by Nektar Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Nektar Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 183.62 M outstanding shares of which 2.01 M shares are now shorted by private and institutional investors with about 1.41 trading days to cover. Nektar Therapeutics currently holds about 546.39 M in cash with (192.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Nektar Therapeutics Probability Of Bankruptcy
Ownership Allocation
Nektar Therapeutics maintains a total of 183.62 Million outstanding shares. Over half of Nektar Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Nektar Therapeutics. Please watch out for any change in the institutional holdings of Nektar Therapeutics as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nektar Ownership Details

Nektar Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of Nektar Therapeutics jumping above the current price in 90 days from now is about 5.8%. The Nektar Therapeutics probability density function shows the probability of Nektar Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 4.9036. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Nektar Therapeutics will likely underperform. Additionally, the company has an alpha of 0.3886, implying that it can generate a 0.39 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 0.85HorizonTargetOdds Above 0.85
94.17%90 days
 0.85 
5.80%
Based on a normal probability distribution, the odds of Nektar Therapeutics to move above the current price in 90 days from now is about 5.8 (This Nektar Therapeutics probability density function shows the probability of Nektar Stock to fall within a particular range of prices over 90 days) .

Nektar Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Nektar Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Nektar Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nektar Therapeutics' value.
InstituionRecorded OnShares
Tang Capital Management Llc2023-09-30
3.9 M
Two Sigma Advisers, Llc2023-12-31
3.1 M
Assenagon Asset Management Sa2023-12-31
2.5 M
Marshall Wace Asset Management Ltd2023-12-31
2.4 M
Two Sigma Investments Llc2023-12-31
2.2 M
Geode Capital Management, Llc2023-12-31
M
Goldman Sachs Group Inc2023-12-31
1.7 M
Millennium Management Llc2023-12-31
1.6 M
Point72 Asset Management, L.p.2023-09-30
1.5 M
Deep Track Capital, Lp2023-12-31
18.4 M
Vanguard Group Inc2023-12-31
12 M
View Nektar Therapeutics Diagnostics

Nektar Therapeutics Historical Income Statement

Nektar Therapeutics Income Statement is one of the three primary financial statements used for reporting Nektar's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Nektar Therapeutics revenue and expense. Nektar Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Nektar Therapeutics' Total Revenue is relatively stable compared to the past year. As of 03/18/2024, Other Operating Expenses is likely to grow to about 258 M, while Interest Expense is likely to drop slightly above 23.9 M. View More Fundamentals

Nektar Stock Against Markets

Picking the right benchmark for Nektar Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Nektar Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Nektar Therapeutics is critical whether you are bullish or bearish towards Nektar Therapeutics at a given time. Please also check how Nektar Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Nektar Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Nektar Therapeutics Corporate Directors

Nektar Therapeutics corporate directors refer to members of a Nektar Therapeutics board of directors. The board of directors generally takes responsibility for the Nektar Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Nektar Therapeutics' board members must vote for the resolution. The Nektar Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Lutz LingnauIndependent DirectorProfile
Roy WhitfieldIndependent DirectorProfile
Scott GreerIndependent DirectorProfile
Christopher KueblerIndependent DirectorProfile

How to buy Nektar Stock?

Before investing in Nektar Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Nektar Therapeutics. To buy Nektar Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Nektar Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Nektar Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Nektar Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Nektar Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Nektar Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Nektar Stock please use our How to Invest in Nektar Therapeutics guide.

Already Invested in Nektar Therapeutics?

The danger of trading Nektar Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Nektar Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Nektar Therapeutics. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Nektar Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Nektar Therapeutics is a strong investment it is important to analyze Nektar Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nektar Therapeutics' future performance. For an informed investment choice regarding Nektar Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any Company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Nektar Stock analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Fundamental Analysis
View fundamental data based on most recent published financial statements
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.45)
Revenue Per Share
0.474
Quarterly Revenue Growth
0.085
Return On Assets
(0.15)
Return On Equity
(1.11)
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.